In vitro diagnostics company Theradiag (Paris:ALTER) (ISIN:FR0004197747) on Friday reported revenues of EUR5.5m for the six months ended 30 June 2021.

This marks an improvement of 12.5% when compared with revenues of EUR4.9m in the first half of 2020, despite an economic and public health context characterised by persistent difficulties accessing hospital treatment for patients undergoing immunotherapy in all countries.

As of 30 June 2021, the company recorded EUR1.4m in net available cash, over EUR3.5m at 31 December 2020. This difference is the result of cash lags of EUR0.5m, as well as investments in R&D and international development, in line with its strategic plan.

The company said it has continued its growth, increasing by +14.7% for theranostics in H1, notably driven by dynamic sales of the automated i-Track10. Theranostics testing measures the efficacy of biotherapy in the treatment of chronic inflammatory diseases.